.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02A_Antifibrinolytics.B02AA02_TranexamicAcid.TranexamicAcid .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B02A_Antifibrinolytics.B02AA02_TranexamicAcid.TranexamicAcid| name: | TranexamicAcid |
| ATC code: | B02AA02 | route: | intravenous |
| n-compartments | 1 |
Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation, thereby preventing fibrinolysis and stabilizing blood clots. It is primarily used to treat or prevent excessive bleeding in various medical conditions, including during surgery, trauma, heavy menstrual bleeding (menorrhagia), and in certain bleeding disorders. Tranexamic acid is approved for use in many countries worldwide.
Single-dose intravenous administration in healthy adult volunteers.
González Osuna, A, et al., & Valle, M (2022). Population Pharmacokinetics of Intra-articular and Intravenous Administration of Tranexamic Acid in Patients Undergoing Total Knee Replacement. Clinical pharmacokinetics 61(1) 83–95. DOI:10.1007/s40262-021-01043-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34255299
Li, S, et al., & Gobburu, JVS (2021). Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. British journal of clinical pharmacology 87(9) 3531–3541. DOI:10.1111/bcp.14767 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33576009
Grassin-Delyle, S, et al., & Shakur-Still, H (2022). Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: a prospective, randomised, crossover trial in healthy volunteers. British journal of anaesthesia 128(3) 465–472. DOI:10.1016/j.bja.2021.10.054 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34998508